The California Public Employees' Retirement System (CalPERS) has been reported to hold 388,000 shares of Strategy (MSTR). This is not a direct purchase of Bitcoin (BTC), but rather an indirect exposure through shares of a publicly traded company that holds a significant amount of BTC. According to 13F data provider Stockzoa, CalPERS' holdings in Strategy were valued at $49 million (approximately 69.3 billion KRW) as of March 31, 2026. CalPERS' latest 13F report, submitted on August 14, 2026, for the second quarter, indicated a total of 1,061 holdings with a combined value of $177.384494 billion (approximately 251 trillion KRW). Strategy disclosed to the SEC that it held 840,738 BTC as of May 25, 2026. The assets held by CalPERS are in Strategy stock, which is linked to BTC price fluctuations. In a statement on July 13, 2026, CalPERS announced a preliminary investment return of 14.8% for the 2025-2026 fiscal year. Any changes in CalPERS' holdings will be confirmed in subsequent 13F filings.
This content is provided for general informational purposes only and doesn't constitute financial, investment, legal, or tax advice. Any events, rewards, online promotions, or related information mentioned herein should not be considered a recommendation, solicitation, or invitation to purchase, sell, trade, or otherwise deal in any crypto assets. Crypto assets are highly volatile and may result in loss. The availability of WEEX services, products, and related events may vary by region. You are responsible for ensuring that your participation is in accordance with applicable local laws and regulations.




Moderna shares more than doubled on 19 August 2026 after Merck and Moderna said the Phase 3 INTerpath-001 trial of intismeran autogene plus KEYTRUDA met its recurrence-free survival endpoint in resected melanoma. This page explains what the result is, why the stock reacted this hard, what is still unknown, which dates come next (presentation and earnings, both unconfirmed), and what a trader can actually do on WEEX — which does not list Moderna; the nearest instrument is the XBI-USDT biotech ETF perpetual. No price targets, no forecasts.















Long-end U.S. Treasury yields surged to multi-year highs, pressuring technology, semiconductor, storage, and optical communication stocks and driving a clear cooling in market risk appetite. At the same time, Anthropic’s revenue came in below some bullish expectations, prompting investors to reassess the AI growth narrative; Unitree Robotics officially listed on the STAR Market, extending momentum in robotics and embodied AI; while SpaceX and other commercial space names showed relative resilience. Investors are now focused on tonight’s Federal Reserve minutes for clearer signals on the policy path and broader market sentiment.











Moderna shares more than doubled on 19 August 2026 after Merck and Moderna said the Phase 3 INTerpath-001 trial of intismeran autogene plus KEYTRUDA met its recurrence-free survival endpoint in resected melanoma. This page explains what the result is, why the stock reacted this hard, what is still unknown, which dates come next (presentation and earnings, both unconfirmed), and what a trader can actually do on WEEX — which does not list Moderna; the nearest instrument is the XBI-USDT biotech ETF perpetual. No price targets, no forecasts.